Literature DB >> 16309457

Immunologic memory in cutaneous leishmaniasis.

Phillip Scott1.   

Abstract

Leishmania major infections induce solid immunity to reinfection. Experimental studies in mice indicate that the CD4+ T cells responsible for this immunity include two populations: parasite-dependent T effector cells and parasite-independent central memory T (Tcm) cells. While there currently is no vaccine for leishmaniasis, the existence of a long-lived population of Tcm cells that does not require the continued presence of live parasites suggests that a vaccine that expands these cells might be efficacious.

Entities:  

Mesh:

Year:  2005        PMID: 16309457     DOI: 10.1111/j.1462-5822.2005.00626.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  16 in total

1.  Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.

Authors:  Shraddha Kumari; Mukesh Samant; Prashant Khare; Pragya Misra; Sujoy Dutta; Bala Krishna Kolli; Sharad Sharma; Kwang Poo Chang; Anuradha Dube
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

Review 2.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Previous exposure to a low infectious dose of Leishmania major exacerbates infection with Leishmania infantum in the susceptible BALB/c mouse.

Authors:  Catherine S Nation; Blaise Dondji; Gabrielle A Stryker
Journal:  Parasitol Res       Date:  2012-04-04       Impact factor: 2.289

4.  CD45RO+ T Cells and T Cell Activation in the Long-Lasting Immunity after Leishmania infantum Infection.

Authors:  João F Rodrigues-Neto; Gloria R Monteiro; Tatjana S L Keesen; Henio G Lacerda; Edgar M Carvalho; Selma M B Jeronimo
Journal:  Am J Trop Med Hyg       Date:  2017-12-21       Impact factor: 2.345

5.  Histopathological features of skin lesions in patients affected by non-ulcerated or atypical cutaneous leishmaniasis in Honduras, Central America.

Authors:  Carmen Maria Sandoval Pacheco; Gabriela Venicia Araujo Flores; Aurea Favero Ferreira; Wilfredo Sosa Ochoa; Vânia Lúcia Ribeiro da Matta; Concepción Zúniga Valeriano; Carlos Eduardo Pereira Corbett; Marcia Dalastra Laurenti
Journal:  Int J Exp Pathol       Date:  2018-11-27       Impact factor: 1.925

6.  Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process.

Authors:  Ifeoma Okwor; Dong Liu; Stephen M Beverley; Jude E Uzonna
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-06       Impact factor: 11.205

7.  Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand.

Authors:  Ann E Field; Sagie Wagage; Sean M Conrad; David M Mosser
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

8.  Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment.

Authors:  Luiza C Reis; Maria Edilenza F Brito; Marina A Souza; Angela C R Medeiros; Claudio J Silva; Carlos F Luna; Valéria R A Pereira
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

Review 10.  Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology.

Authors:  Kenneth J Gollob; Lis R V Antonelli; Daniela R Faria; Tatjana S L Keesen; Walderez O Dutra
Journal:  Int Immunopharmacol       Date:  2008-10       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.